Oscar Health is expected to report a Q3 2026 loss of $0.11 per share on consensus revenue of $4.72 billion, representing a substantial 58.1% year-over-year expansion. The stock currently trades at approximately $30.37, sitting roughly 16% below the average analyst price target of $36.40.
Investors are primarily focused on the Medical Loss Ratio (MLR), which is projected to improve to 85.1% for the quarter, compared to 88.5% in the prior-year period.
This earnings report follows the company's successful transition to full-year profitability and continued member growth in the ACA marketplace. Analysts are particularly attentive to management's ability to manage medical utilization costs and their strategic outlook for the upcoming 2027 open enrollment cycle.